Discover investment opportunities in Best Small Cap Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Small Cap Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Small Cap Biotech Stocks using our Smart AI Filter.
7 stocks found for "Best Small Cap Biotech Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.01 | ±61.6% | -6.4 | 0.00% | |||
2.32 | ±96.8% | -0.7 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.90 | ±63.6% | -4.0 | 0.00% | |||
0.64 | ±36.1% | -9.3 | 0.00% | |||
0.93 | ±47.7% | 25.5 | 0.00% | |||
0.91 | ±96.3% | -1.4 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What makes ARQT (Arcutis Biotherapeutics, Inc.) attractive for growth-seeking investors?
A: Arcutis Biotherapeutics focuses on developing topical treatments for common dermatological conditions, a rapidly growing part of the biotech industry. Its innovative therapies and ongoing clinical trials suggest potential for significant future growth, though past performance is not indicative of future results.
Q: Does ORTX (Orchard Therapeutics plc) offer potential for long-term investors?
A: Orchard Therapeutics is involved in gene therapy for rare diseases. Some investors see long-term potential due to its specialized treatments and niche market position. However, the company's future success is closely tied to regulatory approvals and market adoption.
Q: Are dividends a common feature of small-cap biotech stocks like KPTI (Karyopharm Therapeutics Inc.)?
A: Small-cap biotech stocks, including Karyopharm Therapeutics, typically do not focus on paying dividends. They often prioritize reinvesting earnings into research and development to accelerate growth and innovation.
Q: What sector-specific risks are associated with investing in VERU (Veru Inc.)?
A: Veru Inc., like many biotech firms, faces risks such as dependency on clinical trial outcomes, regulatory approvals, and potential volatility in stock prices due to market perceptions and industry developments.
Q: How does ADMA (ADMA Biologics, Inc.) contribute to income potential in biotech investments?
A: ADMA Biologics focuses on producing plasma-based biologics which have consistent demand, suggesting potential for stable revenue. However, these factors do not guarantee income, and investors should analyze market conditions and company performance closely.
Q: Why might EIGR (Eiger BioPharmaceuticals, Inc.) be considered for a diversified biotech portfolio?
A: Eiger BioPharmaceuticals specializes in rare disease treatments, providing diversification through targeting less competitive niches. This can help mitigate risk across a biotechnology investment portfolio.